The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 501–600 of 748
Hemminki, O., Oksanen, M., Taipale, K., Liikanen, I., Koski, A., Joensuu, T. K., Kanerva, A., & Hemminki, A. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.04.003 · Cited by 8
PEGylation of Goldbody: PEG-aided conformational engineering of peptides on gold nanoparticles
Gao, T., Liu, Y.-Y., Lou, C., Wang, H., Liu, Y., & Cao, A. (2022) · RSC Advances · doi:10.1039/d2ra03903f · Cited by 8
Yang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y., & Shen, Z. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0201 · Cited by 9
Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts
Szadai, L., Bartha, Á., Plá, I., Lakatos, A. I. T., Pal, D., Lengyel, A., de Almeida, N. P., Jánosi, Á. J., Nogueira, F. C. S., Szeitz, B., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428182 · Cited by 9
Kfoury, M., Disdero, V., Vicier, C., Saux, O. L., Gougis, P., Sajous, C., & Vignot, S. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.04.011 · Cited by 8
Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
Passiglia, F., Commendatore, O., Vitali, M., & Conca, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0098 · Cited by 10
Administration of fusion cytokines induces tumor regression and systemic antitumor immunity
Zhang, J., & Zhao, X. (2021) · MedComm · doi:10.1002/mco2.68 · Cited by 8
Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management
Parikh, M., & Powles, T. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_323835 · Cited by 9
Ecology of Fear: Spines, Armor and Noxious Chemicals Deter Predators in Cancer and in Nature
Peplinski, J., Malone, M. A., Fowler, K. J., Potratz, E. J., Pergams, A. G., Charmoy, K. L., Rasheed, K., Avdieiev, S. S., Whelan, C. J., & Brown, J. S. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.682504 · Cited by 9
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
Giglio, A. D., Federico, A. D., Deiana, C., Ricciuti, B., Brambilla, M., & Metro, G. (2022) · Drugs in Context · doi:10.7573/dic.2022-2-4 · Cited by 8
It’s T Time for Normal Blood Vessels
Thienpont, B., & Lambrechts, D. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.005 · Cited by 9
Bagley, S. J., Hwang, W., Brem, S. S., Linette, G. P., O’Rourke, D. M., & Desai, A. S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03010-0 · Cited by 8
Heeke, S., Delingette, H., Fanjat, Y., Long-Mira, É., Lassalle, S., Hofman, V., Benzaquen, J., Marquette, C., Hofman, P. M., & Ilié, M. (2019) · Annales de Pathologie · doi:10.1016/j.annpat.2019.01.003 · Cited by 9
Immunotherapy in the management of squamous cell carcinoma of the head and neck
Subramaniam, S., Paterson, C., & McCaul, J. A. (2019) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2019.08.002 · Cited by 11
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
de Joode, K., Heersche, N., Basak, E. A., Bins, S., van der Veldt, A. A. M., van Schaik, R. H. N., & Mathijssen, R. H. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102662 · Cited by 9
Lymphocyte‐Mimicking Sonosensitizers Boost Cancer Immunotherapy via Sequential Ultrasound Activation
Zhu, J., Wang, X., Li, R., Zhang, T., An, L., Song, X., Dong, X., & Cai, Y. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509057 · Cited by 7
Bettariga, F., Taaffe, D. R., Borsati, A., Avancini, A., Pilotto, S., Lazzarini, S. G., López, P., Maestroni, L., Crainich, U., Bandini, E., et al. (2025) · Journal of Cancer Survivorship · doi:10.1007/s11764-025-01873-7 · Cited by 11
Valous, N. A., Moraleda, R. R., Jäger, D., Zörnig, I., & Halama, N. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101411 · Cited by 9
Wu, J., Mao, L., Sun, W., Yang, X., Wang, H., Liu, X., Chi, K., Huang, X., & Lin, D. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207448 · Cited by 8
Suresh, P. K., Banerjee, A., & Singh, P. (2023) · OpenNano · doi:10.1016/j.onano.2023.100134 · Cited by 8
Lazebnik, T., & Keren, L. S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107221 · Cited by 8
Dolati, M., Vandghanooni, S., Veisi, K., & Jaymand, M. (2024) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2024.100463 · Cited by 11
Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment
Liu, Q., Zhu, W., Song, F., Lou, T., He, L., Zhou, W., & Feng, Z. (2024) · Meta-Radiology · doi:10.1016/j.metrad.2024.100098 · Cited by 8
Tiersma, J. F., Evers, B., Bakker, B. M., Reijngoud, D., de Bruyn, M., de Jong, S., & Jalving, M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102802 · Cited by 8
Najri, B. A., Saidi, K. M., Guendouzi, A., Khelili, S., & Kıvrak, A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142482 · Cited by 7
Novel Biomarkers and Druggable Targets in Advanced Melanoma
Ferrucci, P. F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers14010081 · Cited by 8
What dictates tumour cell sensitivity to exercise?
Campbell, J. P., Walzik, D., & Zimmer, P. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01001-z · Cited by 8
Sequential immunotherapy regimens—expect the unexpected
Serra-Bellver, P., Valpione, S., & Lorigan, P. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30198-x · Cited by 7
Overview of Basic Immunology and Translational Relevance for Clinical Investigators
Stephen, B., & Hajjar, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_1 · Cited by 8
Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma
Lin, W., Lin, A., Li, Z., Zhou, C., Chen, C., Chen, B., Lyu, Q., Zhang, J., & Luo, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110633 · Cited by 8
NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment
Wen, H., Suzuki, T., Zhang, A., Sato, M., Matsumoto, M., Takahashi, Y., Takahashi, Y., & Yamamoto, M. P. (2025) · iScience · doi:10.1016/j.isci.2025.113519 · Cited by 12
Tariq, T., Yar, M., Bayach, I., & Alsadun, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-36405-5 · Cited by 7
Rad, N. K., Vahidyeganeh, M., Mohammadi, M., Shpichka, A. I., Timashev, P. S., Hossein‐Khannazer, N., & Vosough, M. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2040042 · Cited by 6
Patterns of immune equilibrium and escape in indolent and progressing tumors
Pandey, A., Linxweiler, M., Kuo, F., Marti, J. L., Roman, B. R., Ehdaie, B., Vos, J. L., & Morris, L. G. T. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.003 · Cited by 6
Kuang, X., Xu, R., & Li, J. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104357 · Cited by 7
Kijima, T., Kubo, T., Nishihara, D., Nukui, A., Hirohashi, Y., Torigoe, T., & Kamai, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-14700-1 · Cited by 7
Wang, M., Zhang, Y., Liu, M., Wang, Y., Niu, X., Qiu, D., Xi, H., Zhou, Y. Y., Chang, N., Xu, T., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-480 · Cited by 7
Current markers and their value in the era of immuno-oncology
von Rundstedt, F.-C., & Necchi, A. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.11.11 · Cited by 6
Computational methods in tumor immunology
Bhinder, B., & Elemento, O. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.01.001 · Cited by 7
Laryngeal Tumor Microenvironment
Karpathiou, G., Dumollard, J. M., & Péoc’h, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_5 · Cited by 6
Xu, J., Solban, N., Wang, Y., Ferguson, H. M., Perera, S. A., Lin, K. Y., Cai, M., Miller, P. L., Schutt, E. G., Larsen, C. T., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100154 · Cited by 6
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
Ros, J., Gonzalez, N. S., Salvà, F., Baraibar, I., Alonso, G., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040016 · Cited by 8
Genomics Driving Diagnosis and Treatment of Inborn Errors of Immunity With Cancer Predisposition
Barmettler, S., Sharapova, S. O., Milota, T., Greif, P. A., Magg, T., & Hauck, F. H. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.03.012 · Cited by 7
Koczka, K., Rigo, R., Batuyong, E., Cook, S. B., Asad, M., Vallerand, I. A., Suo, A. E., Wang, E., & Cheng, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5070 · Cited by 6
The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer
Wu, Z., & Wu, S. (2022) · Current Urology · doi:10.1097/cu9.0000000000000133 · Cited by 7
Digital pathology in immuno-oncology – a roadmap for clinical development
Ung, C., Kockx, M. M., & Waumans, Y. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1281737 · Cited by 6
Sun, B., Chen, L., Yu, L., Zhang, L., Sun, T., Liu, Y., & Zheng, C. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae087 · Cited by 6
Pezzicoli, G., Musci, V., Ciciriello, F., Salonne, F., Cafforio, P., Lionetti, N., Ragno, A., & Rizzo, M. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241298500 · Cited by 5
A system review of neoadjuvant immune checkpoint blockade for breast cancer
Ye, Y., Zhang, Z., Zhao, H., & Zhao, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1537926 · Cited by 5
Döscher, J., Busch, C., Schuler, P. J., & Laban, S. A. (2016) · HNO · doi:10.1007/s00106-016-0241-8 · Cited by 5
Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy
Prior, L. M., Toomey, S., Greally, M., Keane, F., Lim, M. C. J., Harrold, E. C., O’Keane, C., Bulger, K., Hennessy, B. T., Furney, S. J., et al. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000636 · Cited by 5
Cancer diagnosis by biosensor-based devices: types and challenges
Manna, K., Mukherjee, N., Chatterjee, N., & Saha, K. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823424-2.00017-x · Cited by 7
Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes
Chao, B. N., Carrick, D. M., Filipski, K. K., & Nelson, S. A. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0583 · Cited by 6
Review on Immuno-Oncology Agents for Cancer Therapy
Dhakad, G. G., Shirsat, S. P., & Tambe, K. P. (2022) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2022.00008 · Cited by 5
Germline genetic host factors as predictive biomarkers in immuno-oncology
Chat, V., Ferguson, R., & Kirchhoff, T. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.08.001 · Cited by 6
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression
Drakes, M. L., & Stiff, P. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_3 · Cited by 7
Jiang, Z., Cinti, C., Taranta, M., Mattioli, E., Schena, E., Singh, S., Khurana, R., Lattanzi, G., Tsinoremas, N. F., & Capobianco, E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206686 · Cited by 5
Immune Modulatory Effects of Radiotherapy
Frey, B., Rückert, M., & Gaipl, U. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-52619-5_106-1 · Cited by 8
Bermudez, M. V., & Papa, S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez402 · Cited by 5
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition
Santis, F. D., Fucà, G., Schadendorf, D., Mantovani, A., Magnani, L., Lisanti, M. P., Pettitt, S. J., Bellone, M., Sal, G. D., Minucci, S., et al. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.02.001 · Cited by 6
Towards Predictive Biomarkers for Immunotherapy Response in Breast Cancer Patients
Voorwerk, L., Kat, M., & Kok, M. (2018) · Breast Cancer Management · doi:10.2217/bmt-2017-0014 · Cited by 4
Kurose, K., Sakaeda, K., Fukuda, M., Sakai, Y., Yamaguchi, H., Takemoto, S., Shimizu, K., Masuda, T., Nakatomi, K., Kawase, S., et al. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.004 · Cited by 5
Masuda, T., Ueo, H., Okumura, Y., Kai, Y., ANDO, Y., Masuguchi, K., KITAGAWA, M., Kitagawa, A., Hayashi, N., Tsuruda, Y., et al. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20373 · Cited by 4
Yang, C., Cao, F., & He, Y. (2023) · Medical Science Monitor · doi:10.12659/msm.940157 · Cited by 5
Scibilia, K., Schlicke, P., Schneller, F., & Kuttler, C. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109287 · Cited by 4
It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data
Spencer, C. N., Wells, D. K., & LaVallee, T. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2018.12.003 · Cited by 4
Un tour d’horizon du développement de biomarqueurs pour les anticorps PD-1 et PD-L1 en cancérologie
Chaput, L., & Jordheim, L. P. (2021) · Therapies · doi:10.1016/j.therap.2021.06.005 · Cited by 4
Wang, Y., Liu, X., Yu, K., Xu, S., Qiu, P., Zhang, X., Wang, M., & Xu, Y. (2022) · iScience · doi:10.1016/j.isci.2023.106330 · Cited by 6
Buiting, H. M., Botman, F., van der Velden, L., Brom, L., van Heest, F. B., Bolt, E. E., de Mol, P., & Bakker, T. J. E. M. (2023) · Primary Health Care Research & Development · doi:10.1017/s1463423622000500 · Cited by 4
Shao, F., Jin, K., Li, B., Liu, Z., Zeng, H., Wang, Y., Zhu, Y., Xu, L., Xu, J., Wang, Z., et al. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.07.006 · Cited by 3
Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy
Sultana, Z., Jamil, Z., Samanta, A., Alam, S. S. M., Ali, S., & Hoque, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18770-4.00015-9 · Cited by 4
Zhao, J., Zhuang, W., Sun, B., Bai, H., Wang, Z., Zhong, J., Wan, R., Liu, L., Duan, J., & Wang, J. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15295 · Cited by 7
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
Pusztaszeri, M. P., Bongiovanni, M., & Brimo, F. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22223 · Cited by 4
Brummer, O., Pölönen, P., Mustjoki, S. M., & Brück, O. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.15.503955 · Cited by 14
Loughrey, M. B. (2022) · Colorectal Disease · doi:10.1111/codi.16416 · Cited by 4
Fang, M., Hu, Y., Wang, T., Su, Y., Lu, T., Zhang, H., Li, J., Xie, C., & Gong, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s512808 · Cited by 4
T cell exhaustion landscapes and therapeutic modulation in cancer immunity
Bautista, J., & López‐Cortés, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1827716 · Cited by 5
Immunoplasticity in cutaneous melanoma: beyond pure morphology
Bosisio, F. M., & van den Oord, J. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2058-y · Cited by 6
Integrated noninvasive diagnostics for prediction of survival in immunotherapy
Yeghaian, M., Bodalal, Z., Bucho, T. M. T., Kurilova, I., Blank, C. U., Smit, E. F., van der Heijden, M. S., Nguyen‐Kim, T. D. L., van den Broek, D. A., Beets‐Tan, R. G. H., et al. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100723 · Cited by 8
Elbehi, M. A. (2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.6 · Cited by 6
Wijnen, S. C. M. A., Dimitriadis, P., Reijers, I. L. M., Menzies, A. M., Long, G. V., Wessels, L. F. A., & Blank, C. U. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04094-0 · Cited by 5
RETRACTED: Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy
Xie, L., & Wang, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1638060 · Cited by 5
RetractedMathematical modeling of the effect of early detection in breast cancer treatment
Saad, F. T., Gambo, Y. Y., Wongsantisuk, P., Ahmed, I., & Tariboon, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1626435 · Cited by 4
Review on Immuno-Oncology agents for Cancer Therapy
Dhakad, G. G., Shirsat, S. P., Tambe, K. P., Kairnar, V., & Jain, R. S. (2022) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2022.00017 · Cited by 3
Huo, C. W., Gunadasa, I., Gkolia, P., Shackleton, M. J., & Hunn, M. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000864 · Cited by 3
Borch, A., Bjerregaard, A.-M., de Lima, V. A. B., Østrup, O., Yde, C. W., Eklund, A. C., Mau‐Sørensen, M., Barra, C., Svane, I. M., Nielsen, F. C., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1058605 · Cited by 4
Fröhlich, F., Ramelyte, E., Turko, P., Dzung, A., Freiberger, S. N., Mangana, J., Levesque, M. P., & Dummer, R. (2023) · Cancers · doi:10.3390/cancers15153818 · Cited by 4
Nanomedicine – Immune System Interactions: Limitations and Opportunities for the Treatment of Cancer
Elsafy, S., Metselaar, J. M., & Lammers, T. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_685 · Cited by 4
Kim, Y.-H., Choi, Y. D., Ahn, S., Kim, Y., Oh, I., Park, C., Nam, T.-K., Yoon, M. S., Jeong, J., Cho, I. J., et al. (2024) · Chonnam Medical Journal · doi:10.4068/cmj.2024.60.1.40 · Cited by 3
Prognostic and predictive role of the tumor immune landscape
Haanen, J. B. A. G., & Blank, C. U. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03255-0 · Cited by 5
Molekulare Prädiktoren in der Immunonkologie
Weichert, W. (2018) · Der Pathologe · doi:10.1007/s00292-018-0508-9 · Cited by 3
Hooiveld-Noeken, J. S., Fehrmann, R. S. N., de Vries, E. G. E., & Jalving, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.11.002 · Cited by 3
Emerging clinical pharmacology topics in drug development and precision medicine
Liu, Q., Gilbert, J. A., Zhu, H., Huang, S. M., Kunkoski, E., Das, P., Bergman, K. L., Buschmann, M. M., & ElZarrad, M. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00028-8 · Cited by 3
Immunotherapy for Renal Cell Carcinoma
Qu, L., Wu, D., He, H., Xu, X., & Chen, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.77377 · Cited by 3
Immunotherapeutics in metastatic cancer management
Shukla, M., Shri, P., Mahobiya, S. K., & Vishwakarma, R. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-03561-5 · Cited by 3
Schuiveling, M., van Duin, I. A. J., ter Maat, L. S., van der Weerd, J. C., Verheijden, R. J., van den Berkmortel, F. W. P. J., Blank, C. U., Breimer, G. E., Burgers, F. H., Boers‐Sonderen, M. J., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116831 · Cited by 2
Zhao, Z., Wang, J., Xiong, X., Zhang, S., Yang, M., Wu, H. B., Liu, X., Ma, X., Chen, Y., Qiao, Y., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01957-1 · Cited by 2
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions
Bach, D., Hoang, V. H., Pham, T. V., Nguyen, D. D., & Nguyen, T. L. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04425-w · Cited by 2
Darr, C., Hilser, T., Kesch, C. V., Isgandarov, A., Reis, H., Wahl, M., Virchow, I., Hadaschik, B. A., & Grünwald, V. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000373 · Cited by 2
Fabrication and anticancer evaluation of colchicine bound liposomes in Colon Cancer Cell Line
Shaarawy, N. E., Hassan, A. M., Shafaa, M. W., Hammam, M., & Ibrahim, A. (2023) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2023.208921.7934 · Cited by 2
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.